Connect with us

BioPharma

Kona Gold Solutions Inc (OTCMKTS: KGKG) Strong March Northbound as Beverage Operator Launches Ooh La Lemin Sparkling Lemonade

Published

on

Kona Gold Solutions Inc (OTCMKTS: KGKG) is making a powerful run straight northbound since reversing off $0.0033 lows. The stock is picking up steam and getting noticed by penny stock speculators as the stock sees a substantial surge of trading volume. KGKG is expecting big things in the coming months; the Company forecasted $325,000 in revenue for February and closed out the month with approximately $345,000 in revenue between its two subsidiaries, Kona Gold LLC and Gold Leaf Distribution LLC.  Kona Gold Beverage is on track to having its first quarter with one million plus in revenue. 

It’s easy to get excited about KGKG here as the Company launches its new Ooh La Lemin Sparkling Lemonade. Gluten and GMO-free Ooh La Sparkling Lemonade is available in six delicious flavors: Blue Raspberry, Citrus Splash, Cucumber Watermelon, Huckleberry, Original, and Pineapple Mango. Ooh La Lemin Sparkling will hit Walmart and mortar stores in June. Kona Gold Beverage is laying the ground work to have a phenomenal year with both of its subsidiaries.  The Company is seeing demand grow on a daily basis for its Ooh La Lemin Lemonades and new Sparkling Lemonades.  The rebranding of the Company’s popular hemp energy drink, Kona Gold, will debut in Q2. In addition, the Company anticipates to see big revenue growth in Q2 with its beverage brands and has forecasted out production in 2022 to keep up with demand. 

Kona Gold Solutions Inc (OTCMKTS: KGKG) has created wholly owned subsidiaries, Kona Gold LLC, HighDrate, LLC, and Gold Leaf Distribution, LLC. Kona Gold, LLC has developed a premium Hemp Infused Energy Drink line. HighDrate, LLC has developed the beverage industry’s first CBD Infused Energy Water, available in 6 delicious flavors. Gold Leaf Distribution, LLC was created to fill the Company’s distribution needs in markets it wants to quickly enter. The Companies are located on the east coast of Florida in Melbourne and Greer, South Carolina. KGKG currently has 2.5 billion shares authorized and 778,052,603 shares outstanding. 

Microcapdaily first reported on KGKG on March 1, 2016 stating at the time: “KGKG has exploded onto the scene trading big volume and making a spectacular move up after the Company announced its Energy Drinks and Shots just landed on Amazon.com. This is UNQT reincarnated and this time they seem to have got it right with KGKG landing smack dab in the middle of two of the most explosive sectors out there; pot stocks are heating up across the board and these are some of the biggest runners on the bb’s and we don’t have to tell you about penny stocks and new beverage lines; these two have a very long history of spectacular runners.” 

Earlier this year KGKG developed and launched a new line of beverages, called Ooh La Lemin Sparkling Lemonade.  Ooh La Lemin Sparkling is being produced in 12oz sleek cans; made with all natural ingredients; gluten and GMO free; and has 10 low calories.  Ooh La Lemin Sparkling is available in six delicious flavors: Blue Raspberry, Citrus Splash, Cucumber Watermelon, Huckleberry, Original, and Pineapple Mango. The Sparkling Water category is one of the fastest growing categories in beverage, and Kona Gold identified an opportunity to take advantage of that by creating the first shelf stable, all-natural, sparkling, and low-calorie lemonade in the market.  Sales in the non-Alcohol Sparkling Water category in the USA will be close to $34 Billion USD in 2021, and the category is expected to double again within the next 2-4 years. 

Kona Gold has already received commitments from distributors for its Ooh La Lemin Sparkling Lemonades. Additionally, the Company has several meetings set up in the next two months with large distributors and big box stores interested in selling the Company’s new Sparkling Lemonades.

 

To Find out the inside Scoop on KGKG Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

KGKG

Ooh La Lemin Sparkling will hit Walmart and mortar stores in June. The Company’s 16 oz Ooh La Lemin Lemonades, available in 4 flavors, will be included in modular sets in all stores with 12 ft or wider coolers in select states starting in June of 2022. The Company will announce which states at a later date as it gets closer to launch.  The 4 flavors of Ooh La Lemin will be in Walmart’s system nationwide, which will give the Company fire power to secure distribution in states where it’s currently lacking. 

On March 10 KGKG announced the launch of its all-new Sparkling Ooh La Lemin Lemonades.  Sparkling Ooh La Lemin is formulated with all natural ingredients, contains zero sugar, high in vitamin C, GMO and gluten-free, made with real fruit juice, and only 10 calories.  This is the Company’s first all-natural beverage line as it continues to create leading products in the better-for-you space.  The Company recently exhibited at the 2022 SE Petro Show in Myrtle Beach, SC and the Sparkling Ooh La Lemin Lemonades were a huge hit with buyers, store owners, and distributors that sampled them at the Company’s booth.  Sparkling Ooh La Lemin comes in 12 oz sleek cans and is available in 6 delicious flavors: Blue Raspberry, Citrus Splash, Cucumber Watermelon, Huckleberry, Original, and Pineapple Mango. 

The Company is already in the process of working with buyers at several national big box stores and large grocery chains in the Southeast United States.  Being that Sparkling Ooh La Lemin is an all-natural beverage, this also creates opportunities for the Company to approach health conscience grocery chains.  The Company’s team is currently working on setting up meetings with buyers at the leading chains in this health category.  Sparkling Ooh La Lemin can be immediately purchased from the Company’s Ooh La Lemin website and will be available on Amazon and Walmart Marketplace in the coming days. 

KGKG CEO Robert Clark stated: “I am excited to be announcing the launch of our new Sparkling Ooh La Lemin Lemonades. We have already sent out samples to several buyers and distributors around the country and everyone wants meetings.  We have never seen this kind of demand for a product and with it hitting several hot categories like sparkling and better-for-you, we strongly feel this product line is going to be a huge hit with our consumers. We recently exhibited at the SE Petro Show and everyone that sampled our Sparkling Lemonades at our booth was blown away by how great every flavor tasted and that it was 100% natural.  We cannot wait to get this in consumers hands around the country and will be updating shareholders in the near future on new distribution partnerships and chain deals.” 

For More on KGKG Subscribe Right Now!

KGKG is making a powerful run straight northbound since reversing off $0.0033 lows. The stock is picking up steam and getting noticed by penny stock speculators as the stock sees a substantial surge of trading volume. KGKG is expecting big things in the coming months; the Company forecasted $325,000 in revenue for February and closed out the month with approximately $345,000 in revenue between its two subsidiaries, Kona Gold LLC and Gold Leaf Distribution LLC.  Kona Gold Beverage is on track to having its first quarter with one million plus in revenue. It’s easy to get excited about KGKG here as the Company launches its new Ooh La Lemin Sparkling Lemonade. Gluten and GMO-free Ooh La Sparkling Lemonade is available in six delicious flavors: Blue Raspberry, Citrus Splash, Cucumber Watermelon, Huckleberry, Original, and Pineapple Mango. Ooh La Lemin Sparkling will hit Walmart and mortar stores in June. Kona Gold Beverage is laying the ground work to have a phenomenal year with both of its subsidiaries.  The Company is seeing demand grow on a daily basis for its Ooh La Lemin Lemonades and new Sparkling Lemonades.  The rebranding of the Company’s popular hemp energy drink, Kona Gold, will debut in Q2. In addition, the Company anticipates to see big revenue growth in Q2 with its beverage brands and has forecasted out production in 2022 to keep up with demand. We will be updating on KGKG when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with KGKG.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in KGKG either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.